This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Concert Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$2.04
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

Jan 22

Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Jan 11

Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Aug 27

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

May 25

Concert Pharma EPS beats by $0.02

May 04

Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Feb 27

Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia

Feb 01

Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Jan 23

How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

Dec 19

A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Nov 23

Concert Pharma EPS beats by $0.15

Nov 05

Concert Pharma launches late-stage study of CTP-543 in hair loss disorder

Nov 03

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if CNCE's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if CNCE's dividend payments have been increasing.

Dividendenrendite im Vergleich zum Markt

Concert Pharmaceuticals Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CNCE im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CNCE)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (CNCE)	n/a

Bemerkenswerte Dividende: Unable to evaluate CNCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate CNCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as CNCE has not reported any payouts.

This company has been acquired

Concert Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

Price target decreased to US$13.67

Co-Founder notifies of intention to sell stock

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib Thrive-Aa1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Concert Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

CinCor Pharma hits 52-week high on data for antihypertensive agent

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for Second CTP-543 Phase 3 Clinical Trial in Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target increased to US$14.10

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell Microcap Value Index

Concert Pharmaceuticals: A Balanced Risk/Reward

Concert Pharmaceuticals, Inc. Announces the Publication of Safety and Efficacy Data from the Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 2 Clinical Trial for CTP-543

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Concert Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Consensus revenue estimates fall by 60%

Full year 2021 earnings: EPS exceeds analyst expectations

Concert Pharmaceuticals, Inc. Announces Phase 3 Trials for Moderate to Severe Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Concert Pharmaceuticals, Inc. Announces Not Stand for Re-Election of Ronald W. Barrett as Independent Director

Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Concert Pharmaceuticals, Inc. Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.78 loss per share (vs US$0.60 loss in 3Q 2020)

Price target decreased to US$13.00

Price target decreased to US$14.17

Price target decreased to US$14.67

Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.41 loss in 2Q 2020)

Consensus revenue estimates increase to US$32.0m

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell 3000E Value Index

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Consensus revenue estimates fall to US$1.80m

First quarter 2021 earnings released: US$0.67 loss per share (vs US$0.70 loss in 1Q 2020)

Concert Pharmaceuticals Reports CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023

Concert Pharma EPS beats by $0.02

Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: US$2.40 loss per share (vs US$3.29 loss in FY 2019)

Concert Pharmaceuticals, Inc. Provides Update on Clinical Programs

New 90-day low: US$6.85

Co-Founder notifies of intention to sell stock

Concert Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Concert Pharmaceuticals, Inc. Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia

New 90-day low: US$7.51

Price target lowered to US$19.14

Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia

Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

New 90-day high: US$13.07

How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

New 90-day high: US$12.53

A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Analysts increase revenue estimates to US$6.32m

Earnings miss expectations

Third quarter 2020 earnings released: US$0.60 loss per share

Concert Pharma EPS beats by $0.15

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharma launches late-stage study of CTP-543 in hair loss disorder

Concert Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: US$12.08

New 90-day high: US$11.21

Concert Pharmaceuticals, Inc. Completes CTP-692 Phase 2 Trial Enrollment in Patients with Schizophrenia

Earnings released

Stabilität und Wachstum des Zahlungsverkehrs